40 Stocks Moving In Wednesday's Mid-Day Session

40 Stocks Moving In Wednesday's Mid-Day Session


  • Biofrontera Inc. BFRI shares jumped 109.5% to $5.51 after Roth Capital initiated coverage on the stock with a Buy rating and a $20 price target.
  • Longeveron Inc. LGVN gained 48.1% to $25.50 after tumbling 39% on Tuesday. The company last week announced the FDA granted Rare Pediatric Disease designation for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome.
  • Ocuphire Pharma, Inc. OCUP jumped 38% to $4.80 after the company announced that the first subjects have been enrolled in the MIRA-3 Phase 3 pivotal trial evaluating Nyxol Eye Drops in the reversal of pharmacologically-induced mydriasis.
  • Better Therapeutics, Inc. BTTX shares gained 29% to $8.32 after Chardan Capital initiated coverage on the stock with a Buy rating and a $17 price target.
  • Bridgeline Digital, Inc. BLIN jumped 23.5% to $3.43.
  • Grom Social Enterprises, Inc. GROM gained 23.5% to $2.78. Grom Social Enterprises disclosed that its newest division, Curiosity Ink Media, unwrapped Santa.com.
  • Benessere Capital Acquisition Corp. BENE jumped 21.3% to $12.34. eCombustible Energy will merge with Benessere Capital Acquisition Corp. in a $805 million deal.
  • Spark Networks SE LOV gained 15% to $3.0699. Spark Networks 10% owner Osmium Diamond Lp acquired a total of 1654197 shares at an average price of $2.51.
  • Local Bounti Corporation LOCL jumped 14.8% to $9.20.
  • BIOLASE, Inc. BIOL rose 14.4% to $0.4810 after Nasdaq granted the company 180-day extension to meet minimum bid price requirement. The company also entered into favorable credit deal.
  • Reviva Pharmaceuticals Holdings, Inc. RVPH gained 12.6% to $3.83. Reviva Pharmaceuticals recently posted a Q3 loss of $0.12 per share.
  • Engine Gaming and Media, Inc. GAME rose 12.5% to $3.5780 after the company reported Q4 2021 and FY21 revenue was higher year over year.
  • Pure Storage, Inc. PSTG rose 10.8% to $30.23 after the company reported better-than-expected Q3 EPS and sales results and issued Q4 and FY22 sales guidance above estimates.
  • Golden Ocean Group Limited GOGL rose 9% to $8.71 after reporting Q3 results.
  • HP Inc. HPQ rose 9% to $35.10 after the company reported better-than-expected results for its fourth quarter and issued strong earnings forecast for the current quarter.
  • Meiwu Technology Company Limited WNW shares rose 6.1% to $3.31.

Check out these big penny stock gainers and losers


  • Vallon Pharmaceuticals, Inc. VLON fell 34.3% to $4.79 after jumping over 80% on Tuesday.
  • Qualigen Therapeutics, Inc. QLGN shares dipped 30.9% to $1.7699 after jumping around 105% on Tuesday.
  • Pasithea Therapeutics Corp. KTTA declined 30.2% to $3.9100. Pasithea Therapeutics priced its 8.68 million share private placement at $3.50 per share.
  • Nordstrom, Inc. JWN shares fell 28.5% to $22.81 after the company reported worse-than-expected Q3 sales results. Jefferies downgraded Nordstrom from Buy to Hold and lowered the price target from $48 to $30.
  • Petros Pharmaceuticals, Inc. PTPI fell 26.1% to $1.7294 after jumping over 75% on Tuesday.
  • Aptevo Therapeutics Inc. APVO fell 25.4% to $12.70. Aptevo Therapeutics shares climbed 163% on Tuesday after the company announced a clinical update for its Phase 1b Expansion trial evaluating APVO436 in the treatment of AML. Preliminary data observed to date includes one complete remission.
  • Esperion Therapeutics, Inc. ESPR shares fell 23.6% to $7.64 after surging over 40% on Tuesday.
  • The Gap, Inc. GPS fell 21.5% to $18.44 after the company reported worse-than-expected Q3 EPS and sales results and cut FY21 adjusted EPS guidance below estimates.
  • Clarus Therapeutics Holdings, Inc. CRXT shares fell 21.5% to $4.5001. Clarus Therapeutics shares jumped 43% on Tuesday after the company was granted a U.S. Patent titled 'Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same.'
  • iSpecimen Inc. ISPC fell 21% to $10.42. iSpecimen shares jumped over 48% on Tuesday on continued upward momentum after the company announced it has been contracted to support new advanced research on COVID-19 seeking insights on its transmissibility, variants, outcomes, and testing validity among multiple population segments.
  • Outlook Therapeutics, Inc. OTLK fell 20.5% to $1.24 after the company reported a $10 million bought deal offering of common stock.
  • Gracell Biotechnologies Inc. GRCL fell 19.5% to $6.27. Gracell Biotechnologies shares gained 22% on Tuesday after the company reported members of its senior management team intend to use personal funds to buy up to $2 million in company ADSs in the open market over the next 3 months.
  • Anaplan, Inc. PLAN shares fell 18.8% to $42.28 after the company reported Q3 earnings results. Piper Sandler downgraded Anaplan from Overweight to Neutral and lowered the price target from $77 to $48.
  • Kura Oncology, Inc. KURA declined 16% to $13.95 after the company announced the FDA placed the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML) on a partial clinical hold.
  • Noah Holdings Limited NOAH dropped 15.7% to $37.12 following Q3 results. JP Morgan downgraded Noah Holdings from Overweight to Neutral and announced a $50 price target.
  • MediciNova, Inc. MNOV shares fell 14.7% to $3.7689 after surging 44% on Tuesday.
  • Autodesk, Inc. ADSK shares fell 14.6% to $259.28. Autodesk reported upbeat results for its third quarter, but issued disappointing guidance. Autodesk said it sees Q4 revenue of $1.185 billion to $1.2 billion and non-GAAP earnings of $1.41 to $1.47 per share.
  • Viomi Technology Co., Ltd VIOT slipped 14.2% to $3.50 following Q3 results.
  • NerdWallet, Inc. NRDS dropped 13% to $22.10. The company recently priced its IPO at $18 per share.
  • Nuvation Bio Inc. NUVB fell 12.3% to $8.10.
  • TDCX Inc. TDCX dropped 10.8% to $20.19 following Q3 results.
  • Dillard's, Inc. DDS fell 9.2% to $372.59.
  • Abercrombie & Fitch Co. ANF fell 6.4% to $38.49. Abercrombie & Fitch recently reported third-quarter FY21 sales growth of 10% year-on-year, to $905.16 million, beating the analyst consensus of $896.86 million.
  • Faraday Future Intelligent Electric Inc. FFIE fell 6.4% to $6.15 after the company received anticipated letter from Nasdaq regarding form 10-Q filing.

Posted In: Mid-Day MoversTop GainersNewsPenny StocksSmall CapIntraday UpdateMarketsMoversTrading Ideas